InvestorsHub Logo
Followers 483
Posts 61598
Boards Moderated 14
Alias Born 09/20/2001

Re: abew4me post# 278141

Friday, 10/23/2020 2:11:06 PM

Friday, October 23, 2020 2:11:06 PM

Post# of 469767
Actually, I think we've got a lot of that covered:

Stephen Toutain:

Stephan Toutain, Senior Vice President of Operations, brings more than 25 years of drug development, general management, operations, commercial development, market access, and sales and marketing leadership with particular expertise in neurology and orphan drug markets globally. Before joining Anavex, he held the role of CCO at Interleukin Genetics. He also worked with Alnylam Pharmaceuticals to build its early access program. Previously, he led Global Commercial Development for Sarepta Therapeutics and served as General Manager for Alexion Pharmaceuticals in Europe. Mr. Toutain has also held various U.S. commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson. He received a Master of Business Administration from the University of North Carolina, and a Master of Engineering in Biotechnology from the University of Nancy II in France.

Stephan Toutain appointed Senior Vice President of Operations
https://www.anavex.com/anavex-life-sciences-strengthens-management-team-board-directors/

Toutain's linked in profile lists expanded access
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147884394

Toutain DD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147172095
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146739245


From last year's DD:https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149887343



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News